EHI recently commenced an internal workshop focused on utilizing the Cytiva NanoAssemblr™ Ignite system to generate messenger RNA lipid nanoparticles (mRNA-LNPs) for vaccine development. The workshop was conducted at the EHI laboratory and supported by Cytiva and PT Fluida Teknika. EHI believes that a strong collaboration between research and industry partners is necessary to advance cutting-edge biomedical technologies in Indonesia.
The workshop was led by Anastasia Darwitan, PhD, Field Application Scientist (APAC) from the Nanomedicine Department in Cytiva, and was attended by EHI scientists from the Infectious Disease Vaccine (IDV) group. Through hands-on training and in-depth theoretical discussions, participants gained practical experience in formulating mRNA-LNPs using the NanoAssemblr Ignite platform, strengthening EHI’s internal capacity in next-generation vaccine technology.
This initiative marks a significant milestone, as EHI becomes one of the first laboratories in Indonesia to utilize the NanoAssemblr Ignite system for generating mRNA-LNPs in the development of a vaccine candidate. The workshop underscores EHI’s full commitment to advancing proactive health research through continuous innovation in vaccine and immunotherapy research and development, supporting national and global efforts to address infectious diseases through state-of-the-art scientific approaches.
